Stay updated with breaking news from Interventional Cardiovascular Programs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- Late-Breaking Data Show VASCEPA/VAZKEPA Significantly Reduced STEMI by 40% and NSTEMI by 27% in Pre-Specified, Post Hoc Analyses -- -- Data Presented During Late-Breaking Science Session at European
Investegate announcements from Amarin Corporation plc, REDUCE-IT Exploratory Post Hoc Biomarker Sub-Analysis Shows Relatively Small Changes in Inflammatory Markers Between Icosapent Ethyl and Placebo
Iocyte AMI-3 Trial to assess effectiveness and safety of FDY-5301 in improving outcomes for anterior STEMI patients undergoing primary PCI
GuruFocus Article or News written by GuruFocusNews and the topic is about:
/PRNewswire/ -- An evidence-based approach to clinical trial oversight is key to the future of clinical trial oversight, according to Deepak Bhatt, MD and...